Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 5/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | MAPT | P10636 | 4/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.54 |
| ▸ | FNTA | P49354 | 1/20 | 0.54 |
| ▸ | FNTB | P49356 | 1/20 | 0.54 |
| ▸ | BCHE | P06276 | 1/20 | 0.53 |
| ▸ | ACHE | P22303 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29756365 | 1.00 | PKM (0.62) | PKMMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL9854721 | 0.86 | CDK4 (0.65) | MEN1KMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL1852400 | 0.85 | PKM (0.64) | PKMMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL29992703 | 0.85 | PKM (0.64) | PKMMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL7502247 | 0.84 | ALDH1A1 (0.69) | MEN1KMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL23127272 | 0.82 | ICMT (0.51) | PKMKMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL16982084 | 0.81 | TSHR (0.63) | KDM4ETSHRHTR2AHTR2C | |
| SCHEMBL1855433 | 0.81 | NPSR1 (0.59) | PKMMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL1853982 | 0.80 | GAA (0.61) | PKMMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL1854197 | 0.79 | MEN1 (0.80) | PKMMEN1KMT2AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304571-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) | 2025-10-02 | — | — | US | disclosed |
| EP-3442971-B1 | ESTROGEN RECEPTOR MODULATORS | RECURIUM IP HOLDINGS LLC (US) | 2024-09-25 | — | — | EP | disclosed |
| US-11780834-B2 | Solid forms of 3-((1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azetidin-3- yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol and processes for preparing fused tricyclic compounds comprising a substituted phenyl or pyridinyl moiety, including methods of their use | GENENTECH, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780834-B2 | Solid forms of 3-((1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azetidin-3- yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol and processes for preparing fused tricyclic compounds comprising a substituted phenyl or pyridinyl moiety, including methods of their use | GENENTECH, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| EP-3810283-B1 | SOLID FORMS OF THE TARTRATE SALT OF 3-((1R,3R)-1-(2,6-DIFLUORO-4-((1-(3-FLUOROPROPYL)AZETIDIN-3-YL)AMINO)PHENYL)-3-METHYL-1,3,4,9-TETRAHYDRO-2H-PYRIDO[3,4-B]INDOL-2-YL)-2,2-DIFLUOROPROPAN-1-OL, PROCESS FOR THEIR PREPARATION AND METHODS OF THEIR USE IN TREATING CANCERS | HOFFMANN LA ROCHE (CH) | 2023-06-14 | — | — | EP | disclosed |
| CN-112679495-B | Estrogen receptor modulators | 里科瑞尔姆IP控股有限责任公司 | 2023-03-28 | — | — | CN | disclosed |
| CN-110382496-B | Substituted pyrido [3,4-b ] indoles for the treatment of cartilage disorders | 赛诺菲 | 2022-08-09 | — | — | CN | disclosed |
| CN-113717170-A | Estrogen receptor modulators | 里科瑞尔姆IP控股有限责任公司 | 2021-11-30 | — | — | CN | disclosed |
| US-20210330651-A1 | ESTROGEN RECEPTOR MODULATORS | RECURIUM IP HOLDINGS, LLC | 2021-10-28 | — | — | US | disclosed |
| CN-109311870-B | Estrogen receptor modulators | 里科瑞尔姆IP控股有限责任公司 | 2021-09-21 | — | — | CN | disclosed |
| US-8088795-B2 | Cyclic-alkylamine derivatives as inhibitors of the interaction between MDM2 and p53 | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-01-03 | — | — | US | disclosed |
| US-20110053937-A1 | Inhibitors of the Interaction Between MDM2 and P53 | LACRAMPE JEAN FERNAND ARMAND | 2011-03-03 | — | — | US | disclosed |
| US-7834016-B2 | Inhibitors of the interaction between MDM2 and p53 | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-16 | — | — | US | disclosed |
| EP-1809622-B1 | INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | JANSSEN PHARMACEUTICA NV (BE) | 2010-07-21 | — | — | EP | disclosed |
| US-20100168163-A1 | CYCLIC-ALKYLAMINE DERIVATIVES AS INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | JANSSEN PHARMACEUTICAL N.V. (BE) | 2010-07-01 | — | — | US | disclosed |
| US-20100168163-A1 | CYCLIC-ALKYLAMINE DERIVATIVES AS INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | JANSSEN PHARMACEUTICAL N.V. (BE) | 2010-07-01 | — | — | US | disclosed |
| US-20080039472-A1 | Inhibitors of the Interaction Between Mdm2 and P53 | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-14 | — | — | US | disclosed |
| WO-2007107545-A1 | CYCLIC-ALKYLAMINEDERIVATIVES AS INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-09-27 | — | — | WO | disclosed |
| EP-1809622-A1 | INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-25 | — | — | EP | disclosed |
| WO-2006032631-A1 | INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053937-A1 | Inhibitors of the Interaction Between MDM2 and P53 | TP53, MDM2, TP53BP1 | PKM 1728/4885MEN1 978/4885KMT2A 2688/4885 |
| US-11780834-B2 | Solid forms of 3-((1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azetidin-3- yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol and processes for preparing fused tricyclic compounds comprising a substituted phenyl or pyridinyl moiety, including methods of their use | TP53, DPYD, FLI1 | PKM 856/4885MEN1 1111/4885KMT2A 184/4885 |
| US-20250304571-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | VHL, BRCA1, TERT | PKM 1165/4885MEN1 301/4885KMT2A 1604/4885 |
| US-20210330651-A1 | ESTROGEN RECEPTOR MODULATORS | ESR2, GPER1, ESRRG | PKM 1904/4885MEN1 3935/4885KMT2A 3296/4885 |
| US-20080039472-A1 | Inhibitors of the Interaction Between Mdm2 and P53 | TP53, MDM2, TP53BP1 | PKM 1728/4885MEN1 978/4885KMT2A 2688/4885 |
| US-20100168163-A1 | CYCLIC-ALKYLAMINE DERIVATIVES AS INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | TP53, MDM2, TP53BP1 | PKM 1391/4885MEN1 1255/4885KMT2A 1433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.